AREV Life Sciences Global Corp.
AREV
CNSX
| 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | |
|---|---|---|---|---|---|
| Net Income | 75.97% | 28.19% | -313.65% | 131.78% | 69.55% |
| Total Depreciation and Amortization | 0.00% | 0.98% | -51.89% | -14.86% | -4.96% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 0.00% | -98.79% | 133.88% | -745.08% | -88.32% |
| Change in Net Operating Assets | 187.67% | -118.81% | -55.30% | -37.87% | -44.85% |
| Cash from Operations | 95.13% | -365.95% | -400.00% | -156.06% | 106.60% |
| Capital Expenditure | -- | -- | -- | -- | 100.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | 100.00% |
| Total Debt Issued | -100.00% | 156.57% | 480.23% | -195.56% | -- |
| Total Debt Repaid | -- | -- | -- | -- | 0.00% |
| Issuance of Common Stock | -- | -100.00% | -- | -- | -100.00% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -100.00% | 31.58% | 853.97% | -75.00% | -103.45% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 82.28% | -181.72% | 361.26% | -470.00% | 156.60% |
